{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:14:24Z","timestamp":1790626464157,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As the persistent resistance of <jats:italic>Staphylococcus aureus<\/jats:italic> to available antibiotics is associated with high infection incidence, mortality rate and treatment cost, novel antibacterial agents with innovative therapeutic targets must be developed. 3,3\u2032-(4-Nitrobenzylidene)-bis-(4-hydroxycoumarin) (NBH), a dicoumarin derivative, was reported to exert antibacterial activity. This study investigated the underlying mechanisms of <jats:italic>in vivo<\/jats:italic> and <jats:italic>in vitro<\/jats:italic> activities of NBH against <jats:italic>S. aureus<\/jats:italic>. NBH exerted bactericidal effects against the tested <jats:italic>S. aureus<\/jats:italic> and <jats:italic>Staphylococcus epidermidis<\/jats:italic> strains <jats:italic>in vitro<\/jats:italic>, with low cytotoxicity and resistance and high plasma stability. NBH also exhibited therapeutic effects <jats:italic>in vivo<\/jats:italic> on septicaemic mice. Results of molecular docking and analysis on morphological change, DNA production and polymerase inhibition suggested that DNA polymerase could be the target of NBH. These findings indicated that dicoumarin derivatives, which interfere with DNA replication, could be developed as a potential agent against <jats:italic>S. aureus<\/jats:italic>, particularly methicillin-resistant strains.<\/jats:p>","DOI":"10.1038\/srep13637","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T09:19:02Z","timestamp":1441099142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Selective in vivo and in vitro activities of 3,3\u2032-4-nitrobenzylidene-bis-4-hydroxycoumarin against methicillin-resistant Staphylococcus aureus by inhibition of DNA polymerase III"],"prefix":"10.1038","volume":"5","author":[{"given":"Zheng","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,1]]},"reference":[{"key":"BFsrep13637_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.archger.2011.07.003","volume":"55","author":"LY Chen","year":"2012","unstructured":"Chen, L. Y. et al. Treatment of community-onset methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: a hospital-based study. Arch Gerontol Geriatr 55, 152\u2013156 (2012).","journal-title":"Arch Gerontol Geriatr"},{"key":"BFsrep13637_CR2","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.1086\/598187","volume":"48 Suppl 4","author":"A del Rio","year":"2009","unstructured":"del Rio, A., Cervera, C., Moreno, A., Moreillon, P. & Miro, J. M. Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis 48 Suppl 4, S246\u2013253 (2009).","journal-title":"Clin Infect Dis"},{"key":"BFsrep13637_CR3","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","volume":"298","author":"RM Klevens","year":"2007","unstructured":"Klevens, R. M. et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Jama 298, 1763\u20131771 (2007).","journal-title":"Jama"},{"key":"BFsrep13637_CR4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3201\/eid1807.101371","volume":"18","author":"M Pastagia","year":"2012","unstructured":"Pastagia, M., Kleinman, L. C., Lacerda de la Cruz, E. G. & Jenkins, S. G. Predicting risk for death from MRSA bacteremia. Emerg Infect Dis 18, 1072\u20131080 (2012).","journal-title":"Emerg Infect Dis"},{"key":"BFsrep13637_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","volume":"1","author":"K Hiramatsu","year":"2001","unstructured":"Hiramatsu, K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1, 147\u2013155 (2001).","journal-title":"Lancet Infect Dis"},{"key":"BFsrep13637_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1086\/527392","volume":"46","author":"DM Sievert","year":"2008","unstructured":"Sievert, D. M. et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46, 668\u2013674 (2008).","journal-title":"Clin Infect Dis"},{"key":"BFsrep13637_CR7","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/jama.2010.757","volume":"303","author":"M Sanchez Garcia","year":"2010","unstructured":"Sanchez Garcia, M. et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. Jama 303, 2260\u20132264 (2010).","journal-title":"Jama"},{"key":"BFsrep13637_CR8","doi-asserted-by":"publisher","first-page":"963248","DOI":"10.1155\/2013\/963248","volume":"2013","author":"KN Venugopala","year":"2013","unstructured":"Venugopala, K. N., Rashmi, V. & Odhav, B. Review on natural coumarin lead compounds for their pharmacological activity. Biomed Res Int 2013, 963248 (2013).","journal-title":"Biomed Res Int"},{"key":"BFsrep13637_CR9","doi-asserted-by":"publisher","first-page":"10896","DOI":"10.1021\/jm300922h","volume":"55","author":"B Li","year":"2012","unstructured":"Li, B. et al. Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation and antibacterial activities. J Med Chem 55, 10896\u201310908 (2012).","journal-title":"J Med Chem"},{"key":"BFsrep13637_CR10","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.ejmech.2008.03.038","volume":"43","author":"N Hamdi","year":"2008","unstructured":"Hamdi, N., Puerta, M. C. & Valerga, P. Synthesis, structure, antimicrobial and antioxidant investigations of dicoumarol and related compounds. Eur J Med Chem 43, 2541\u20132548 (2008).","journal-title":"Eur J Med Chem"},{"key":"BFsrep13637_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/14756360601114270","volume":"22","author":"X Meng","year":"2007","unstructured":"Meng, X. et al. Inhibition of a thermophilic deoxyribonucleic acid polymerase by fullerene derivatives. J Enzyme Inhib Med Chem 22, 293\u2013296 (2007).","journal-title":"J Enzyme Inhib Med Chem"},{"key":"BFsrep13637_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0076-6879(87)55023-6","volume":"155","author":"KB Mullis","year":"1987","unstructured":"Mullis, K. B. & Faloona, F. A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155, 335\u2013350 (1987).","journal-title":"Methods Enzymol"},{"key":"BFsrep13637_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution. Drug discovery today. Technologies 1, 337\u2013341 (2004).","journal-title":"Drug discovery today. Technologies"},{"key":"BFsrep13637_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2011.05.008","volume":"63","author":"CD Alonso","year":"2011","unstructured":"Alonso, C. D., Barclay, S., Tao, X. & Auwaerter, P. G. Increasing incidence of iliopsoas abscesses with MRSA as a predominant pathogen. J Infect 63, 1\u20137 (2011).","journal-title":"J Infect"},{"key":"BFsrep13637_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.mcna.2013.02.005","volume":"97","author":"PS Pottinger","year":"2013","unstructured":"Pottinger, P. S. Methicillin-resistant Staphylococcus aureus infections. Med Clin North Am 97, 601\u2013619 (2013).","journal-title":"Med Clin North Am"},{"key":"BFsrep13637_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/2110-5820-1-26","volume":"1","author":"HD Spapen","year":"2011","unstructured":"Spapen, H. D. et al. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 1, 26 (2011).","journal-title":"Ann Intensive Care"},{"key":"BFsrep13637_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1128\/AAC.03694-14","volume":"59","author":"M Drouet","year":"2015","unstructured":"Drouet, M. et al. Influence of vancomycin infusion methods on endothelial cell toxicity. Antimicrobial agents and chemotherapy 59, 930\u2013934 (2015).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep13637_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1039\/b416648p","volume":"22","author":"RH Baltz","year":"2005","unstructured":"Baltz, R. H., Miao, V. & Wrigley, S. K. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep 22, 717\u2013741 (2005).","journal-title":"Nat Prod Rep"},{"key":"BFsrep13637_CR19","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","volume":"358","author":"DJ Diekema","year":"2001","unstructured":"Diekema, D. J. & Jones, R. N. Oxazolidinone antibiotics. Lancet 358, 1975\u20131982 (2001).","journal-title":"Lancet"},{"key":"BFsrep13637_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2174\/1389450023347678","volume":"3","author":"NJ Johnston","year":"2002","unstructured":"Johnston, N. J., Mukhtar, T. A. & Wright, G. D. Streptogramin antibiotics: mode of action and resistance. Curr Drug Targets 3, 335\u2013344 (2002).","journal-title":"Curr Drug Targets"},{"key":"BFsrep13637_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","volume":"6","author":"AK Marr","year":"2006","unstructured":"Marr, A. K., Gooderham, W. J. & Hancock, R. E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 6, 468\u2013472 (2006).","journal-title":"Curr Opin Pharmacol"},{"key":"BFsrep13637_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1517\/17460441.2012.660478","volume":"7","author":"G Sanyal","year":"2012","unstructured":"Sanyal, G. & Doig, P. Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin Drug Discov 7, 327\u2013339 (2012).","journal-title":"Expert Opin Drug Discov"},{"key":"BFsrep13637_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.bmcl.2008.12.038","volume":"19","author":"J Guiles","year":"2009","unstructured":"Guiles, J. et al. Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III. Bioorg Med Chem Lett 19, 800\u2013802 (2009).","journal-title":"Bioorg Med Chem Lett"},{"key":"BFsrep13637_CR24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1021\/jm0510023","volume":"49","author":"C Zhi","year":"2006","unstructured":"Zhi, C. et al. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. J Med Chem 49, 1455\u20131465 (2006).","journal-title":"J Med Chem"},{"key":"BFsrep13637_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews 46, 3\u201326 (2001).","journal-title":"Advanced drug delivery reviews"},{"key":"BFsrep13637_CR26","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. Clinical And Laboratory Standards Institute, M100\u2013S122 (2012)."},{"key":"BFsrep13637_CR27","unstructured":"CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard, 9th edition. M7-A9. Clinical And Laboratory Standards Institute, Wayne, PA (2012)."},{"key":"BFsrep13637_CR28","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/jac\/dkt030","volume":"68","author":"N Ooi","year":"2013","unstructured":"Ooi, N. et al. Antibacterial activity and mode of action of tert-butylhydroquinone (TBHQ) and its oxidation product, tert-butylbenzoquinone (TBBQ). J Antimicrob Chemother 68, 1297\u20131304 (2013).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep13637_CR29","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1128\/AAC.00504-13","volume":"57","author":"Z Hou","year":"2013","unstructured":"Hou, Z. et al. R-thanatin inhibits growth and biofilm formation of methicillin-resistant Staphylococcus epidermidis in vivo and in vitro. Antimicrobial agents and chemotherapy 57, 5045\u20135052 (2013).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep13637_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/jac\/dkm244","volume":"60","author":"M Grare","year":"2007","unstructured":"Grare, M. et al. In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria. J Antimicrob Chemother 60, 575\u2013581 (2007).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep13637_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/infdis\/jiq029","volume":"203","author":"Z Hou","year":"2011","unstructured":"Hou, Z. et al. Underlying mechanism of in vivo and in vitro activity of C-terminal-amidated thanatin against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli. J Infect Dis 203, 273\u2013282 (2011).","journal-title":"J Infect Dis"},{"key":"BFsrep13637_CR32","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1128\/AAC.49.10.4210-4219.2005","volume":"49","author":"T Bogdanovich","year":"2005","unstructured":"Bogdanovich, T., Ednie, L. M., Shapiro, S. & Appelbaum, P. C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrobial agents and chemotherapy 49, 4210\u20134219 (2005).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep13637_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"LL Ling","year":"2015","unstructured":"Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455\u2013459 (2015).","journal-title":"Nature"},{"key":"BFsrep13637_CR34","doi-asserted-by":"publisher","first-page":"20695","DOI":"10.1073\/pnas.0809989106","volume":"105","author":"RJ Evans","year":"2008","unstructured":"Evans, R. J. et al. Structure of PolC reveals unique DNA binding and fidelity determinants. Proceedings of the National Academy of Sciences of the United States of America 105, 20695\u201320700 (2008).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep13637_CR35","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1038\/srep05201","volume":"4","author":"R Ilayaraja","year":"2014","unstructured":"Ilayaraja, R. et al. Evaluating the binding efficiency of pheromone binding protein with its natural ligand using molecular docking and fluorescence analysis. Scientific reports 4, 5201 (2014).","journal-title":"Scientific reports"},{"key":"BFsrep13637_CR36","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1038\/srep06015","volume":"4","author":"SM Mandal","year":"2014","unstructured":"Mandal, S. M. et al. Controlling resistant bacteria with a novel class of beta-lactamase inhibitor peptides: from rational design to in vivo analyses. Scientific reports 4, 6015 (2014).","journal-title":"Scientific reports"},{"key":"BFsrep13637_CR37","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1021\/jm020483c","volume":"46","author":"A Ali","year":"2003","unstructured":"Ali, A. et al. Novel pyrazolo[3,4-d]pyrimidine-based inhibitors of Staphlococcus aureus DNA polymerase III: Design, synthesis and biological evaluation. J Med Chem 46, 1824\u20131830 (2003).","journal-title":"J Med Chem"},{"key":"BFsrep13637_CR38","unstructured":"Schrodinger, L. L. C. The PyMOL Molecular Graphics System. Version 1.3r1. (2010)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep13637","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:55:07Z","timestamp":1672962907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep13637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,11,26]]}},"alternative-id":["BFsrep13637"],"URL":"https:\/\/doi.org\/10.1038\/srep13637","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,1]]},"assertion":[{"value":"14 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13637"}}